2,375 results on '"Eikelboom, John W"'
Search Results
2. Improving analysis of cognitive outcomes in cardiovascular trials using different statistical approaches
3. Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials
4. Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial
5. Perioperative management and outcomes in patients receiving low-dose rivaroxaban and/or aspirin: a subanalysis of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial
6. Standard of care in advanced HIV disease: review of HIV treatment guidelines in six sub-Saharan African countries
7. Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation
8. When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review
9. Impact of Frailty on the Benefits of Dual Pathway Inhibition for the Secondary Prevention of Cardiovascular Events in the COMPASS Randomised Trial
10. Results of the COMPASS Trial Analyzed Using Win Ratio Compared With Conventional Analytic Approaches
11. Elevations in Creatine Kinase are Not Related to the Choice or Dose of Statins in Patients Taking Colchicine 0.5 mg Daily: Insights from the LoDoCo2 Trial
12. Single Bolus r-SAK Before Primary PCI for ST-Segment–Elevation Myocardial Infarction
13. Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials
14. Efficacy and safety of a bolus of half-dose r-SAK prior to primary PCI in ST-elevation myocardial infarction: Rationale and design of the OPTIMA-6 trial
15. Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC‐AF risk scores
16. Rationale and design of the colchicine for the prevention of perioperative atrial fibrillation in patients undergoing major noncardiac thoracic surgery (COP-AF) trial
17. Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial
18. The Effect of Years-Long Exposure to Low-Dose Colchicine on Renal and Liver Function and Blood Creatine Kinase Levels: Safety Insights from the Low-Dose Colchicine 2 (LoDoCo2) Trial
19. Abstract 17748: Lipoprotein(a) and Oxidized Phospholipids on Lipoproteins and Cardiovascular Outcomes in Patients With Chronic Coronary Syndrome Treated With Colchicine
20. Abstract 14628: Residual Stroke Risk Among Atrial Fibrillation Patients Treated With Warfarin or Novel Oral Anticoagulants: A Patient Level Meta-Analysis From Combine AF
21. Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trial
22. Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
23. Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
24. P-Selectin de-ACTIVation in COVID-19: What Have We Learned?
25. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors
26. Inflammation as a Mechanism and Therapeutic Target in Peripheral Artery Disease
27. Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low‐dose rivaroxaban, or the combination: Secondary analysis of the COMPASS randomised controlled trial.
28. Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF.
29. Rivaroxaban for Patients with Intermittent Claudication.
30. Carbamazepine, phenytoin, and oral anticoagulants: Drug‐drug interaction and clinical events in a retrospective cohort
31. Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials
32. Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis
33. Perioperative Management and Outcomes in Patients Receiving Low-dose Rivaroxaban and or Aspirin: A Sub-analysis of the COMPASS Trial
34. Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease
35. Cost-effectiveness of low-dose colchicine in patients with chronic coronary disease in The Netherlands
36. Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy
37. Urinary thromboxane and risk of cardiovascular events: role of aspirin
38. Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation
39. What Is the Future of Factor XI Inhibitors?
40. Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and End-Stage Renal Disease: Lessons Learned
41. Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome
42. Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
43. Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial)
44. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review
45. Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reduction
46. Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial
47. Preoperative prediction of Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study
48. Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study establishing diagnostic criteria and prognostic importance
49. Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation
50. Abstract 12361: Efficacy and Safety of NOACs vs. Warfarin Across the Continuous Range of Body Mass Index and Body Weight: Insights From COMBINE-AF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.